Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARDTNASDAQ:FLGTNASDAQ:LFSTNASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDTArdent Health Partners$14.48-1.5%$13.36$11.31▼$20.72$2.07BN/A390,149 shs205,309 shsFLGTFulgent Genetics$20.61$18.76$14.57▼$25.11$627.45M1281,203 shs368,147 shsLFSTLifeStance Health Group$5.95+0.7%$6.32$4.64▼$8.61$2.30B1.31.59 million shs1.49 million shsVCYTVeracyte$26.89-0.3%$29.95$19.73▼$47.32$2.11B2.14900,493 shs1.46 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDTArdent Health Partners0.00%-0.89%+15.16%-1.23%+1,447,999,900.00%FLGTFulgent Genetics0.00%+1.48%+19.48%+33.40%-1.15%LFSTLifeStance Health Group0.00%+8.38%-8.74%-23.62%+5.50%VCYTVeracyte0.00%-0.99%-9.49%-22.64%+29.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDTArdent Health Partners3.3686 of 5 stars3.50.00.00.03.00.03.1FLGTFulgent Genetics3.7296 of 5 stars2.32.00.04.12.64.20.6LFSTLifeStance Health Group2.3824 of 5 stars3.41.00.00.03.32.50.6VCYTVeracyte4.1992 of 5 stars4.43.00.04.32.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDTArdent Health Partners 3.00Buy$20.6742.73% UpsideFLGTFulgent Genetics 2.50Moderate Buy$24.0016.45% UpsideLFSTLifeStance Health Group 2.83Moderate Buy$8.5042.86% UpsideVCYTVeracyte 2.70Moderate Buy$40.9052.10% UpsideCurrent Analyst Ratings BreakdownLatest FLGT, LFST, VCYT, and ARDT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025LFSTLifeStance Health GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.505/20/2025ARDTArdent Health PartnersStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$21.00 ➝ $21.005/15/2025ARDTArdent Health PartnersRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.005/9/2025ARDTArdent Health PartnersGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $18.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/5/2025FLGTFulgent GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.004/9/2025ARDTArdent Health PartnersGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.004/9/2025ARDTArdent Health PartnersMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $18.004/9/2025VCYTVeracyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $37.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDTArdent Health Partners$6.02B0.34N/AN/AN/A∞FLGTFulgent Genetics$292.45M2.15$4.03 per share5.12$38.24 per share0.54LFSTLifeStance Health Group$1.28B1.80N/AN/A$3.77 per share1.58VCYTVeracyte$463.39M4.54$0.06 per share442.29$14.30 per share1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDTArdent Health Partners$53.90M$1.638.887.39N/AN/AN/AN/A8/13/2025 (Estimated)FLGTFulgent Genetics-$167.82M-$1.33N/AN/AN/A-59.39%-1.81%-1.66%8/1/2025 (Estimated)LFSTLifeStance Health Group-$186.26M-$0.10N/AN/AN/A-7.90%-6.66%-4.51%8/14/2025 (Estimated)VCYTVeracyte-$74.40M$0.41N/A37.35N/A-2.18%3.02%2.80%8/5/2025 (Estimated)Latest FLGT, LFST, VCYT, and ARDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025ARDTArdent Health Partners$0.21$0.29+$0.08$0.29$1.50 billion$1.50 billion5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDTArdent Health PartnersN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/ALFSTLifeStance Health GroupN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDTArdent Health Partners0.781.911.78FLGTFulgent GeneticsN/A4.414.41LFSTLifeStance Health Group0.191.321.32VCYTVeracyteN/A5.084.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDTArdent Health PartnersN/AFLGTFulgent Genetics48.06%LFSTLifeStance Health Group85.50%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipARDTArdent Health Partners1.70%FLGTFulgent Genetics33.11%LFSTLifeStance Health Group3.20%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDTArdent Health Partners24,200143.04 millionN/AOptionableFLGTFulgent Genetics1,01030.44 million20.87 millionOptionableLFSTLifeStance Health Group6,640388.88 million357.39 millionOptionableVCYTVeracyte79078.32 million76.49 millionOptionableFLGT, LFST, VCYT, and ARDT HeadlinesRecent News About These CompaniesUniversal Beteiligungs und Servicegesellschaft mbH Purchases New Stake in Veracyte, Inc. (NASDAQ:VCYT)June 1 at 4:40 AM | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by BrokeragesMay 30 at 2:45 AM | marketbeat.comVoloridge Investment Management LLC Reduces Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 29 at 4:29 AM | marketbeat.comVeracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCOMay 29 at 12:57 AM | insidermonkey.comVeracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer ResearchMay 28, 2025 | businesswire.comVeracyte: Upgrading To NeutralMay 26, 2025 | seekingalpha.comPalisades Investment Partners LLC Acquires New Position in Veracyte, Inc. (NASDAQ:VCYT)May 24, 2025 | marketbeat.comMan Group plc Sells 294,029 Shares of Veracyte, Inc. (NASDAQ:VCYT)May 23, 2025 | marketbeat.comDeutsche Bank AG Has $3.22 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 23, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Nuveen Asset Management LLCMay 22, 2025 | marketbeat.comComparing Veracyte (NASDAQ:VCYT) and Grail (NASDAQ:GRAL)May 22, 2025 | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Virtus Investment Advisers Inc.May 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Lowers Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 21, 2025 | marketbeat.comVeracyte to Participate in Upcoming Investor ConferencesMay 20, 2025 | businesswire.comPoint72 Asset Management L.P. Buys Shares of 523,162 Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $7.61 Million Position in Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Bank of America Corp DEMay 20, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 55,684 Shares of Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comVeracyte Stock Surges 30.9% in a Year: What's Driving the Rally?May 19, 2025 | zacks.comLazard Asset Management LLC Boosts Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 19, 2025 | marketbeat.comResearch Analysts Set Expectations for Veracyte Q2 EarningsMay 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLGT, LFST, VCYT, and ARDT Company DescriptionsArdent Health Partners NYSE:ARDT$14.48 -0.22 (-1.50%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$14.48 -0.01 (-0.03%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.Fulgent Genetics NASDAQ:FLGT$20.61 0.00 (0.00%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$20.82 +0.22 (+1.04%) As of 05/30/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.LifeStance Health Group NASDAQ:LFST$5.95 +0.04 (+0.68%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$5.97 +0.02 (+0.34%) As of 05/30/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.Veracyte NASDAQ:VCYT$26.89 -0.07 (-0.26%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$26.62 -0.28 (-1.02%) As of 05/30/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
